{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-049835","form_type":"8-K","ticker":"BDX","cik":"0000010795","company_name":"BECTON DICKINSON & CO","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.740412+00:00","generated_at":"2026-05-16T23:20:48.878952+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"BD Q4 revenue $5.9B (+8.3%); FY25 adjusted EPS $14.40 (+9.6%); FY26 guidance","bullets":["Q4 revenue $5,890M, up 8.3% as reported, 3.9% organic; GAAP EPS $1.72, adjusted EPS $3.96.","FY25 revenue $21.8B (+8.2% as reported); GAAP EPS $5.82 (-0.7%), adjusted EPS $14.40 (+9.6%).","FY25 adjusted operating margin up 80 bps to 25.0%; adjusted gross margin up 140 bps.","Returned $2.2B to shareholders in FY25 via dividends and share repurchases.","Biosciences/Diagnostic Solutions combination with Waters Corp on track to close near end of Q1 CY2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-049835","json":"https://secwatch.observer/filing/0001628280-25-049835.json","markdown":"https://secwatch.observer/filing/0001628280-25-049835.md","text":"https://secwatch.observer/filing/0001628280-25-049835.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/10795/000162828025049835/0001628280-25-049835-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/10795/000162828025049835/bdx-20251106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:20:48.878952+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}